NO20061537L - Fremgangsmate for a levere legemidler til hjernen - Google Patents

Fremgangsmate for a levere legemidler til hjernen

Info

Publication number
NO20061537L
NO20061537L NO20061537A NO20061537A NO20061537L NO 20061537 L NO20061537 L NO 20061537L NO 20061537 A NO20061537 A NO 20061537A NO 20061537 A NO20061537 A NO 20061537A NO 20061537 L NO20061537 L NO 20061537L
Authority
NO
Norway
Prior art keywords
brain
dispersion
particles
pharmaceutical preparation
mammal
Prior art date
Application number
NO20061537A
Other languages
English (en)
Norwegian (no)
Inventor
James E Kipp
Barrett E Rabinow
Howard Gendelman
Original Assignee
Univ Nebraska By And Behalf Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nebraska By And Behalf Of filed Critical Univ Nebraska By And Behalf Of
Publication of NO20061537L publication Critical patent/NO20061537L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20061537A 2003-06-24 2006-04-04 Fremgangsmate for a levere legemidler til hjernen NO20061537L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48209603P 2003-06-24 2003-06-24
PCT/US2004/018850 WO2004112747A2 (fr) 2003-06-24 2004-06-15 Methode d'administration de medicaments au cerveau

Publications (1)

Publication Number Publication Date
NO20061537L true NO20061537L (no) 2006-04-04

Family

ID=33539336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061537A NO20061537L (no) 2003-06-24 2006-04-04 Fremgangsmate for a levere legemidler til hjernen

Country Status (8)

Country Link
US (1) US9044381B2 (fr)
EP (1) EP1663158A2 (fr)
AU (1) AU2004249172A1 (fr)
BR (1) BRPI0414970A2 (fr)
CA (1) CA2540695A1 (fr)
NO (1) NO20061537L (fr)
WO (1) WO2004112747A2 (fr)
ZA (1) ZA200603062B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
AU2004249172A1 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
EP1713443A2 (fr) * 2004-01-29 2006-10-25 Baxter International Inc. Nanosuspensions d'agents antiretroviraux permettant d'ameliorer l'administration dans le systeme nerveux central
EP1753429A1 (fr) * 2004-05-28 2007-02-21 Vertex Pharmaceuticals Incorporated Modulateurs de récepteurs muscariniques
MXPA06011171A (es) 2004-06-15 2007-01-25 Baxter Int Aplicacion ex-vivo de agentes terapeuticos microparticulados solidos.
US20060228420A1 (en) * 2005-03-15 2006-10-12 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons
EP2279726A3 (fr) 2005-05-26 2012-06-20 Biorest Ltd. Compositions et méthodes d'utilisation desdites compositions dans l'administration d'agents dans un organe cible protégé par une barrière sanguine
US20080274202A1 (en) * 2005-08-01 2008-11-06 Kraig Richard P Compositions and Method for Brain Specific Targeted Delivery of Therapeutic Agents
KR100762954B1 (ko) * 2006-01-26 2007-10-04 나재운 항암제가 봉입된, 소수성 담즙산이 결합된 친수성 키토산올리고당 나노입자 및 그 제조방법
KR100785656B1 (ko) * 2007-05-14 2007-12-17 재단법인서울대학교산학협력재단 소염제로 사용되는 소디움글리코콜레이트 또는 그 유도체
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
ES2447465T3 (es) * 2008-03-05 2014-03-12 Baxter International Inc. Partículas de superficie modificada y métodos para la administración dirigida de fármacos
JP5711138B2 (ja) * 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
US8846096B2 (en) * 2008-12-12 2014-09-30 Creighton University Nanoparticles and methods of use
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
DK2462131T3 (en) 2009-08-07 2015-01-05 American Life Science Pharmaceuticals Inc Preparations and Methods for Treating Beta-Amyloid-Related Diseases
EP3513810A1 (fr) * 2010-03-22 2019-07-24 F. Hoffmann-La Roche AG Compositions et procédés utiles pour stabiliser des formulations contenant des protéines
JP2013542945A (ja) * 2010-11-02 2013-11-28 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 治療を送達するための組成物および方法
WO2012138003A1 (fr) * 2011-04-08 2012-10-11 경북대학교 산학협력단 Utilisations d'un dérivé d'héparine-acide biliaire désulfaté pour la prévention et le traitement de maladies inflammatoires
DE102012009570A1 (de) 2012-05-09 2013-11-14 Naum Goldstein Komposition für nasale Anwendung
DE102012015248A1 (de) * 2012-08-05 2014-02-06 Naum Goldstein Verfahren zur Einbringung biologisch aktiver Substanzen ins Gehirn
WO2015108945A2 (fr) 2014-01-14 2015-07-23 Board Of Regents Of The University Of Nebraska Compositions et méthodes pour l'administration d'agents thérapeutiques
EP3203995A4 (fr) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska Compositions et méthodes d'administration d'agents thérapeutiques
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
US11839623B2 (en) 2018-01-12 2023-12-12 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019199756A1 (fr) 2018-04-09 2019-10-17 Board Of Regents Of The University Of Nebraska Promédicaments antiviraux et formulations de ceux-ci
EP4076527A4 (fr) 2020-01-10 2024-05-15 Consynance Therapeutics, Inc. Polythérapies de médicaments et leurs méthodes d'utilisation
EP4093391A1 (fr) * 2020-01-23 2022-11-30 AXCESS (UK) Ltd. Absorption cellulaire
WO2023004113A2 (fr) 2021-07-22 2023-01-26 The Regents Of The University Of California Compositions et méthodes d'utilisation d'enzymes d'édition d'arn humain purifiées

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655801C2 (de) 1976-12-09 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension
DE2656317C2 (de) 1976-12-11 1986-06-19 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren zur Herstellung einer Suspension von beladenen Erythrocyten
DE2656746C2 (de) 1976-12-15 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verwendung von beladenen Erythrozyten
US4670185A (en) 1982-07-19 1987-06-02 Lion Corporation Aqueous vesicle dispersion having surface charge
JPS60150826A (ja) 1984-01-18 1985-08-08 Lion Corp 表面電荷をもつベシクル分散液
US4608278A (en) 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1338736C (fr) 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US5213788A (en) * 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
FR2651680B1 (fr) 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
JPH06504274A (ja) 1991-01-07 1994-05-19 シンジェニックス・リミテッド 微細粒子
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU687359B2 (en) 1992-09-28 1998-02-26 Brown University Research Foundation Chitosan matrices for encapsulated cells
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5720551A (en) 1994-10-28 1998-02-24 Shechter; Tal Forming emulsions
SE9403846D0 (sv) 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
US20050054033A9 (en) 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
WO1997014407A1 (fr) 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Administration de medicaments insolubles
EP0920339A2 (fr) * 1996-07-09 1999-06-09 The Johns Hopkins University Systeme d'administration de genes
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (fr) 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire
AU7133898A (en) 1997-04-18 1998-11-13 Vertex Pharmaceuticals Incorporated Nanosized aspartyl protease inhibitors
US20020068048A1 (en) 1997-09-05 2002-06-06 Patrick A. Dreyfus Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
WO2000006244A2 (fr) 1998-07-30 2000-02-10 Hainfeld James F Particules metalliques de chargement dans des vesicules membranaires cellulaires et particule metallique utilisee pour l'imagerie et la therapie
AU4476600A (en) 1999-04-22 2000-11-10 Vanderbilt University Polymeric encapsulation system promoting angiogenesis
US20050112141A1 (en) 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
HUP0202669A3 (en) 1999-09-09 2004-06-28 Univ California Cationic liposome delivery of taxanes to angiogenic bloos vessels
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
GB0002856D0 (en) 2000-02-08 2000-03-29 Gendel Limited Ultrasound sensitisation
JP4085231B2 (ja) 2000-02-28 2008-05-14 株式会社ビークル タンパク質中空ナノ粒子とそれを用いた物質運搬体、ならびに細胞への物質導入方法
EP1267946A4 (fr) 2000-02-28 2008-07-02 Genesegues Inc Systeme et procede d'encapsulation de nanocapsules
US7338657B2 (en) 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
WO2001082899A2 (fr) 2000-05-03 2001-11-08 Mbt Munich Biotechnology Ag Agents de diagnostic cationique, d'imagerie et de therapie associes a des sites vasculaires actives
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
BR0116377A (pt) 2000-12-22 2005-12-13 Baxter Int Métodos para preparar partìculas submicronicamente dimensionadas de um composto orgânico, e para preparar uma suspensão de um composto farmaceuticamente ativo, e, composição de matéria
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
WO2002060416A1 (fr) 2001-02-01 2002-08-08 Gendel Limited Systeme d'administration de polypeptide et leur procede de preparation
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
US6790455B2 (en) * 2001-09-14 2004-09-14 The Research Foundation At State University Of New York Cell delivery system comprising a fibrous matrix and cells
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
US20050244503A1 (en) 2003-05-19 2005-11-03 Rabinow Barrett E Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents
EP1638460A4 (fr) 2003-06-12 2010-05-05 Univ Minnesota Methode pour diriger des cellules sur des tissus ou des organes cibles
PL1567188T3 (pl) 2003-06-20 2012-12-31 Lilly Co Eli Zmodyfikowane cząstki wirusa o właściwościach immunogennych i zmniejszonej zawartości lipidów użyteczne do leczenia i profilaktyki chorób zakaźnych
AU2004249172A1 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US20050084456A1 (en) 2003-10-21 2005-04-21 Liping Tang Functionalized particles
GB0329310D0 (en) 2003-12-18 2004-01-21 Univ Keele Method
EP1713443A2 (fr) 2004-01-29 2006-10-25 Baxter International Inc. Nanosuspensions d'agents antiretroviraux permettant d'ameliorer l'administration dans le systeme nerveux central
WO2005079854A1 (fr) 2004-02-02 2005-09-01 Engeneic Molecular Delivery Pty Ltd. Compositions et procedes de liberation de medicaments in vitro et in vivo ciblee dans des cellules mammiferes par le biais de minicellules intactes derivees de bacteries
MXPA06011171A (es) 2004-06-15 2007-01-25 Baxter Int Aplicacion ex-vivo de agentes terapeuticos microparticulados solidos.
WO2006080243A1 (fr) 2005-01-28 2006-08-03 Konica Minolta Medical & Graphic, Inc. Particule magnetique enrobee contenant une preparation, un procede de production de celle-ci et un systeme therapeutique de diagnostic
EP1896007B1 (fr) 2005-05-04 2014-03-19 Medigene AG Methode d'administration d'une preparation liposomale cationique contenant du paclitaxel
CN1772303A (zh) 2005-10-25 2006-05-17 朱宏 恶性肿瘤磁热疗用纳米磁粉－抗体靶向药物

Also Published As

Publication number Publication date
US20050048002A1 (en) 2005-03-03
ZA200603062B (en) 2007-04-25
WO2004112747A2 (fr) 2004-12-29
BRPI0414970A2 (pt) 2012-12-11
AU2004249172A1 (en) 2004-12-29
CA2540695A1 (fr) 2004-12-29
US9044381B2 (en) 2015-06-02
WO2004112747A3 (fr) 2005-03-03
EP1663158A2 (fr) 2006-06-07

Similar Documents

Publication Publication Date Title
NO20061537L (no) Fremgangsmate for a levere legemidler til hjernen
Jin et al. Young exosome bio‐nanoparticles restore aging‐impaired tendon stem/progenitor cell function and reparative capacity
Liu et al. Activation of canonical wnt pathway promotes differentiation of mouse bone marrow‐derived MSCs into type II alveolar epithelial cells, confers resistance to oxidative stress, and promotes their migration to injured lung tissue in vitro
Elia et al. Extracellular vesicles from mesenchymal stem cells exert pleiotropic effects on amyloid‐β, inflammation, and regeneration: a spark of hope for Alzheimer's disease from tiny structures?
US20090227550A1 (en) Controlled release delivery system for nasal application of neurotransmitters
CN111328284A (zh) 用于维持和恢复健康的肠道屏障的组合物和方法
Splettstoesser et al. Modulation of voltage‐gated channel currents by harmaline and harmane
CA2876512A1 (fr) Cellules souches de type mesenchymateuses issues de cellules souches embryonnaires humaines, leurs procedes et leurs utilisations
NZ710383A (en) A novel formulation of diclofenac
JP2015523400A (ja) 排出阻害剤およびこれを用いる治療法
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
EP3295943A1 (fr) Agent aqueux de suspension comprenant des nanoparticules de glucocorticostéroïde
JP2020534299A (ja) 神経学的状態を治療するための方法および改善された神経保護組成物
WO2006097725A3 (fr) Preparations pharmaceutiques comprenant des microparticules penetrant les neurones
Solana‐Balaguer et al. Neuron‐derived extracellular vesicles contain synaptic proteins, promote spine formation, activate TrkB‐mediated signalling and preserve neuronal complexity
JP2016510766A (ja) １型糖尿病の処置及び／又は予防のための方法及び組成物
Zhu et al. Outer membrane vesicles of Actinobacillus pleuropneumoniae exert immunomodulatory effects on porcine alveolar macrophages
Zhang et al. Mucus as a barrier for biopharmaceuticals and drug delivery systems
Thomas et al. Targeting Microglia in Neuroinflammation: H3 Receptor Antagonists as a Novel Therapeutic Approach for Alzheimer’s Disease, Parkinson’s Disease, and Autism Spectrum Disorder
CN113474448A (zh) 高复杂度合成肠道细菌群落
El-Halim The possible therapeutic effect of mesenchymal stem cells and their exosomes on experimentally induced diabetic retinopathy in rats: Histological and immunohistochemical study
WO2006030301A8 (fr) Composition pharmaceutique contenant du cilostazol, a base de particules d'une taille inferieure a 50 micrometres
Wang et al. Polydopamine-coated mesoporous silica nanoparticles co-loaded with Ziyuglycoside I and Oseltamivir for synergistic treatment of viral pneumonia
US20170095505A1 (en) Combination of xenon and an antioxidant to control a parkinson's disease-type neurodegenerative disease
Rashchupkin et al. Effect of M2 macrophage-derived soluble factors on proliferation and apoptosis of SH-SY5Y Cells

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application